SecBot SecBot
COURT-RULING ·Filed Apr 13, 2026

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD
NEUTRAL
Impact 5/10
Horizonmonths Processed4mo ago CourtCourt Ruling · courtlistener.com
Court ruling (district)
Actionable Insight • Neutral

The court narrowed the case by dismissing several theories, but left the core DAW campaign, PBM exclusivity, and reclassification petition claims intact, these will proceed to discovery and potentially trial. The case now focuses on Teva's alleged false statements to doctors and exclusionary PBM contracting, which could eventually lead to behavioral remedies or damages. Monitor the related In re Copaxone Antitrust Litigation (No. 22-1232) for parallel developments. Teva's OTC-traded stock may see limited near-term movement as this is a single district court ruling on a motion to dismiss, not a final judgment.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.77
T+0 close · Apr 14, 2026 · via day close
Latest settled
+3.71%
T+60 · $32.95
Vs SPY
−5.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $31.77entry
  2. T+1 · 7mo ago −0.50%α −1.29% · $31.61
  3. T+5 · 7mo ago −1.51%α −2.90% · $31.29
  4. T+20 · 6mo ago +12.72%α +6.42% · $35.81
  5. T+60 · 4mo ago +3.71%α −5.28% · $32.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The District of New Jersey adopted a Special Master's recommendation to partially dismiss Mylan's antitrust lawsuit against Teva regarding Copaxone. The ruling dismissed claims that Teva's 20mg citizen petitions, 20mg ANDA lawsuit, 2014 FDA lawsuit, 40mg ANDA lawsuit, market-shift strategy, and copay assistance program were anticompetitive, finding they were protected by Noerr-Pennington immunity or failed to plausibly allege causation. However, the court allowed Mylan's claims regarding Teva's DAW (Dispense as Written) campaign, exclusionary agreements with PBMs, and the 2020 reclassification petition to proceed, meaning significant antitrust exposure remains for Teva.

Court Ruling Details

Ruling Date
Apr 13, 2026
Court
U.S. District Court for the District of New Jersey
Court Level
District
Judge
Julien Xavier Neals
Case Type
antitrust
Ruling Type
motion to dismiss
Outcome
PARTIAL: mixed ruling, some claims won/lost
Appeal Timeline
Mylan may appeal the dismissal of petitioning/litigation claims within 30 days; otherwise case proceeds to discovery over surviving claims
Precedent Risk
LOW

Key Facts

  • Court adopted Special Master's 91-page R&R partially granting Teva's motion to dismiss Mylan's antitrust complaint
  • DAW campaign allegations, exclusionary PBM agreement allegations, and 2020 reclassification petition claims survive dismissal and will proceed to discovery
  • 20mg citizen petitions, 20mg and 40mg ANDA lawsuits, 2014 FDA lawsuit, market-shift allegations, and copay assistance program allegations dismissed with prejudice under Noerr-Pennington immunity
  • Non-Orange Book patent litigation allegations excluded from complaint as not pled in original filing
  • Foreign regulatory conduct allegations struck from complaint as irrelevant to Sherman Act claims
  • Lanham Act false advertising claim (Count II) and state law claims (Counts III-VI) also survive
  • Copaxone is a $4B+ annual revenue drug for Teva; generic competition via Mylan has been limited since 2017 launch

Financial Impact

No damages awarded. If Mylan eventually wins, potential antitrust damages could be substantial (trebled), but no dollar figure stated in the opinion. Copaxone represented approximately $1.5B in annual Teva revenue as of recent periods.

revenuelegal_exposureantitrust_risk

Risk Factors

  • Surviving claims (DAW campaign, PBM agreements, reclassification petition) will now proceed to costly discovery
  • If Mylan prevails at trial, treble damages under antitrust laws could be material given Copaxone's revenue base
  • Related multi-district litigation (In re Copaxone Antitrust Litig.) may compound exposure
  • DOJ anti-kickback investigation into Teva's copay assistance (referenced in complaint) remains a separate risk
  • Appeal by Mylan on dismissed claims is possible but faces high bar given de novo review and factual findings

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-15mpe8hi-TEVA

Track record

61 reports on TEVA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens in 8h 50m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published Jul 2, 2026